文献速递淋巴瘤

FOLL05试验长期结果:比较R-CVP、R-CHOP与R-FM方案初始治疗晚期症状性滤泡性淋巴瘤

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
PubMed 文献 · J Clin Oncol · 2017-11-02

FOLL05试验比较R-CVP、R-CHOP与R-FM方案(均不加利妥昔单抗维持)初始治疗晚期症状性滤泡性淋巴瘤的长期结局。中位随访7年后,8年总生存率83%,三组间无显著差异;R-CHOP和R-FM较R-CVP显著改善无进展生存,但R-FM较R-CVP非淋巴瘤进展相关死亡风险更高。

要点

  • 中位随访84个月,8年无治疗失败时间44%、无进展生存率48%、总生存率83%。
  • R-CHOP和R-FM较R-CVP显著改善无进展生存(HR分别为0.73和0.67)。
  • 三组8年总生存无显著差异;R-FM较R-CVP非淋巴瘤进展相关死亡风险更高。

核心结论

  • 中位随访7年的FOLL05试验长期随访确认,接受免疫化疗的晚期滤泡性淋巴瘤患者8年总生存率达83%,结局良好。
  • 三个治疗组总生存相似,但活性和毒性特征不同。
  • 初始接受R-CVP治疗的患者较接受R-CHOP者淋巴瘤进展风险更高,需要额外治疗的风险也更高。

研究设计与样本

  • FOLL05试验的事后分析,比较R-CVP、R-CHOP与R-FM方案(均不加利妥昔单抗维持)初始治疗晚期滤泡性淋巴瘤。
  • 共入组534例患者,可评估504例;分析时中位随访84个月(范围1至119个月)。

主要发现

  • 8年无治疗失败率和无进展生存率分别为44%(95% CI,39%至49%)和48%(95% CI,43%至53%)。
  • 经FL国际预后指数2校正的无进展生存风险比:R-CHOP对比R-CVP为0.73(95% CI,0.54至0.98;P=0.037);R-FM对比R-CVP为0.67(95% CI,0.50至0.91;P=0.009)。
  • 8年总生存率为83%(95% CI,79%至87%),各治疗组间无显著差异。
  • R-FM较R-CVP观察到因淋巴瘤进展无关原因死亡的风险更高。

局限性

  • 本文为事后分析(post hoc analysis)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fludarabine and mitoxantrone) regimens without rituximab maintenance as initial therapy for patients with advanced-stage follicular lymphoma (FL). A previous analysis with a median follow-up of 34 months showed a superior 3-year time to treatment failure, the primary study end point, with R-CHOP and R-FM versus R-CVP and showed R-CHOP to have a better risk-benefit ratio in terms of toxicity than R-FM. We report a post hoc analysis of this trial after a median follow-up of 7 years. Patients and Methods Of the 534 enrolled patients, 504 were evaluable. At the time of analysis, the median follow-up was 84 months (range, 1 to 119 months). Results The 8-year time to treatment failure and progression-free survival rates were 44% (95% CI, 39% to 49%) and 48% (95% CI, 43% to 53%), respectively. The hazard ratio for progression-free survival adjusted by FL International Prognostic Index 2 versus R-CVP was 0.73 for R-CHOP (95% CI, 0.54 to 0.98; P = .037) and 0.67 for R-FM (95% CI, 0.50 to 0.91; P = .009). The 8-year overall survival (OS) rate was 83% (95% CI, 79% to 87%), with no significant differences among study arms. Overall, we observed a higher risk of dying as a result of causes unrelated to lymphoma progression with R-FM versus R-CVP. Conclusion With an 83% 8-year OS rate, long-term follow-up of the FOLL05 trial confirms the favorable outcome of patients with advanced-stage FL treated with immunochemotherapy. The three study arms had similar OS but different activity and toxicity profiles. Patients initially treated with R-CVP had a higher risk of lymphoma progression compared with those receiving R-CHOP, as well as a higher risk of requiring additional therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Luminari S, Ferrari A, Manni M, et al. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. J Clin Oncol. 2017. PMID: 29095677. doi:10.1200/JCO.2017.74.1652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。